Replies to post #79547 on Biotech Values

[mcbio]

Re: PCYC MNTA

The problem with this approach to treating cancer is that the anticoagulation cascade does have a lot of margin for error; hence, it will be hard for PCYC (or anyone else) to find a dose that is high enough to have anti-cancer efficacy without also causing severe bleeding (#msg-37030489).

Thanks for the response Dew. Makes sense. Here's a link to the scientific data page on PCYC's Web site: http://www.pharmacyclics.com/wt/page/factor_viia_scientific_data .

In particular, they are trying to make the case that "a selective inhibitor of the Factor VIIa/tissue factor complex may have a greater therapeutic/safety index than inhibition of other coagulation factors." Sounds interesting, but sounds like a longshot.